SCHEMBL25758985

SCHEMBL25758985

CCN1CCC(Cc2ccc(OC)c(OC)c2)CC1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.62
HTR1A P08908 1/20 0.53
SLC6A4 P31645 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
SIGMAR1 Q99720 1/20 0.50
LMNA P02545 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
MAPK1 P28482 2/20 0.49
HSD17B10 Q99714 2/20 0.49
NPC1 O15118 1/20 0.49
KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758964 0.85 ABCB1 (0.61) ABCB1HTR1ASLC6A4SIGMAR1LMNA
SCHEMBL3367454 0.84 CA2 (0.59) ABCB1SIGMAR1LMNAALDH1A1MAPK1
SCHEMBL24069006 0.82 ABCB1 (0.69) ABCB1HTR1ASLC6A4SIGMAR1
SCHEMBL24069044 0.81 ABCB1 (0.54) ABCB1HTR1ASLC6A4SIGMAR1LMNA
SCHEMBL1291749 0.81 CA2 (0.55) ABCB1MEN1KMT2ASIGMAR1LMNA
SCHEMBL12961327 0.81 ABCB1 (0.46) ABCB1HTR1ASLC6A4MEN1KMT2A
SCHEMBL18182316 0.78 MAPK1 (0.72) MEN1KMT2ASIGMAR1RAB9AALDH1A1
SCHEMBL10407811 0.77 SLC6A4 (0.59) ABCB1SLC6A4SIGMAR1
SCHEMBL14401257 0.76 KCNH2 (0.54)
SCHEMBL27015502 0.76 ALDH1A1 (0.47) ALDH1A1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 ABCB1 2037/4885HTR1A 34/4885SLC6A4 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.